For the year ended 30 June 2025, China Health Technology Group Holding Company Limited reported revenue of RMB 90.215 million, compared to RMB 47.606 million for the year ended 30 June 2024. Cost of sales was RMB 82.002 million, up from RMB 45.709 million in the previous year. Gross profit increased to RMB 8.213 million from RMB 1.897 million. Other income amounted to RMB 0.328 million, compared to RMB 0.016 million in the prior year. Other gains, net, were RMB 34.528 million, up from RMB 22.205 million. There was no gain on debt restructuring in 2025, compared to RMB 202.024 million in 2024. Selling and distribution expenses were RMB 0.862 million, down from RMB 1.421 million. Administrative expenses totalled RMB 15.678 million, compared to RMB 21.472 million in the previous year. Revenue by product for 2025: - Sales of timber related products: RMB 36.633 million (2024: RMB 32.521 million) - Sales of ginseng related products: RMB 39.467 million (2024: RMB 15.085 million) - Sales of health products: RMB 14.115 million (2024: nil) Total segment assets as at 30 June 2025 were RMB 196.960 million, compared to RMB 168.605 million as at 30 June 2024. Consolidated total assets amounted to RMB 205.417 million, up from RMB 178.166 million.